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pioglitazone plus metformin (PIO + MET) versus sulphonylurea
plus metformin (SU + MET) oral combination therapies in
patients with insufﬁcient glycaemic control despite maximal tol-
erated dose of metformin monotherapy. METHODS: A decision-
analytic model employing a Markov process was constructed
using TreeAge DATA. The model incorporated efﬁcacy evidence
from a key clinical trial comparing the glycaemic control of PIO
+ MET versus SU + MET, as measured by initial improvements
in HbA1c and the rate of disease progression in terms of HbA1c
(the coefﬁcient of failure). Treatment pathways reﬂecting best
practice in Scotland, including third-line insulin therapy, were
modelled, with published (UKPDS) cost data of diabetes man-
agement and co-morbidity treatment. RESULTS: Patients treated
with PIO + MET achieved better HbA1c control and improved
serum lipid proﬁles, which translated into fewer diabetic com-
plications, better quality of life and improved overall survival.
Additional drug costs of PIO + MET over SU + MET were partly
offset by lower costs to treat and manage diabetes complications,
and delayed third-line insulin therapy. PIO + MET patients
incurred mean additional costs of £1217 per patient and gained
0.05 additional quality-adjusted life years (QALY’s) per patient
compared to SU + MET patients. The estimated incremental cost
per QALY gained of PIO + MET compared to SU + MET was
£25,599. If a QALY is valued at £30,000, PIO + MET is asso-
ciated with a net health beneﬁt of £209 per patient (95% 
conﬁdence interval: -£6679 to £8076). CONCLUSIONS: The
relationship between HbA1c and the incidence of complications
in Type-2 diabetes is well established. Evidence from a large
head-to-head trial indicates superior glycaemic (HbA1c) control
accompanied by signiﬁcantly improved serum lipid proﬁles in
patients treated with PIO + MET. Given that PIO + MET pro-
vides a positive net health beneﬁt, therefore PIO + MET is a cost-
effective intervention relative to current treatment in Type-2
diabetes.
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PHARMACOECONOMIC ASPECTS OF USE OF INSULIN
GLARGINE IN TREATMENT OF DIABETES MELLITUS TYPE 2
(DM T2) IN RUSSIA
Suntsov YI, Dedov II, Komarova VP,Vedeneeva LF
Endocrinology Research Center, Moscow, Russia
OBJECTIVES: To conduct a prognostic evaluation of the total
cost of treatment of DM T2 and its complications, to estimate
the economic effectiveness of the use of insulin glargine.
METHODS: At stage 1, the costs of treatment of 500 patients
in DM T2 from 15 regions of Russia were studied. At stage 2,
the predicted prevalence of complications over 10-year time
interval and their cost was calculated by the Diabetes Mellitus
Model (DMM) using. At stage 3, the total cost of treatment of
DM T2 patients in Russia based on the State Register of Dia-
betes Patients at the moment of the study and prospectively at
the 10th year from the start was calculated. The method of cash
ﬂow discounting according to the formula á = 1/(1 + ri)i was
used, where á is the discounting coefﬁcient, i is the consecutive
number of the period, and ri is the discounting rate in the i-th
period in fractions of a unit. RESULTS: According to data of
previous comparative studies, the use of insulin glargine leads to
reach a lower level of HbA1c versus NPH insulins, and this dif-
ference amounts to 0.85%. Taking into account these data,
decreases in the predicted prevalence at the end of the 10-year
period pro-vided that insulin glargine was used, in comparison
to NPH insulin, would amount to 18% for mi-crovascular com-
plications, 25% for chronic renal insufﬁciency, 10% for
macrovascular complica-tions, 13% for myocardial infarction;
22% for diabetic foot syndrome, and 12% for mortality. The
annual costs of treatment of complications in DM T2 patients
in Russia should decrease by US$246.7 million. CONCLU-
SIONS: The use of the human insulin analogue insulin glargine
in treatment of DM T2 patients allows the cost of treatment to
be decreased mainly due to a decrease in expenditures on treat-
ment of complications.
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COSTS OF TYPE-2 DIABETES MELLITUS: A COMPARISON
BETWEEN DIABETIC AND NON-DIABETIC SUBJECTS
Perelli Cippo P, Scalone L, Mantovani LG
University of Milan, Milan, Italy
OBJECTIVES: Type-2 diabetes mellitus is a common chronic
disease and a costly health care problem. The aims of this study
were to assess the social costs of type-2 diabetes mellitus and to
evaluate the costs of diabetic patients in comparison with non-
diabetic subjects. METHODS: We conducted a Cost of Illness
(COI) analysis from a societal perspective with a 3-month time
horizon. Data were collected from a population based natural-
istic prospective survey, designed to investigate cardiovascular
risk factors in a sample of the Italian general population aged
from 40 to 79 years. We selected all type-2 diabetic patients and
we matched each of them by age and sex with a non-diabetic
subject. Patients were interviewed by general practitioners about
clinical/demographic characteristics, medical resource utilization
and absence from work during the 3 months before the enrol-
ment visit. Direct medical costs were quantiﬁed including hospi-
talizations, drug therapies, specialist visits, diagnostics and
laboratory exams, while indirect costs were estimated based 
on productivity losses with the Human-Capital-approach.
RESULTS: We studied 666 patients, 333 with type-2 diabetes
matched with 333 without the disease. The mean total cost per
patient-month was 228.7€ compared to 169.9€ for patients with
and without type-2 diabetes mellitus, respectively (P < 0.0001).
On average, direct medical cost per patient-month was estimated
at 199.2€ in diabetic patients and 129.1€ in non-diabetic sub-
jects (P < 0.0001). Hospitalizations accounted for the greatest
proportion of health care costs in both groups, followed by drug
therapies (hospitalizations: 65.1% and 59.6%; drug therapies:
24.5% and 29.7% in patients with and without type-2 diabetes,
respectively). There was no statistically signiﬁcant difference in
indirect costs between diabetic and non-diabetic subjects. CON-
CLUSIONS: The results show that type-2 diabetes mellitus
patients aged from 40 to 79 years are more costly than non-
diabetic subjects.
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ECONOMIC EVALUATION OF THE STEPPED VERSUS
ORDINARY CARE FOR PREVENTION OF TYPE-2 DIABETES IN
THE JDPP: JAPAN DIABETES PREVENTION PROGRAM
Yanagisawa S1, Shimaya M1, Nakahara N1, Kamae I1, Kuzuya H2
1Kobe University, Kobe, Japan; 2National Hospital Organization Kyoto
Medical Center, Kyoto, Japan
OBJECTIVES: To perform an economic evaluation for the
primary prevention of typeII diabetes based on the intermediate
report of JDPP. METHODS: At ﬁrst, SF36(V.1.20) and EQ-5D
with Japanese version were applied, surveying over 205 partici-
pants, to assess whether or not the stepped care in JDPP may
change the QOL of the patients with the relevant symptoms of
silence. The second, a decision-analytic model was used to
combine transition probabilities with clinical stages of diabetes,
resource use and cost data in the framework of cost-effectiveness
analysis within three years since 1998. The model employed a
societal perspective to estimate the expected costs for each group
of the stepped vs. ordinary cares which included the direct costs
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for intervention and treatment, and also production loss of
patients as indirect costs. RESULTS: A total of 185 question-
naires on SF-36 and EQ-5D were returned (88 stepped, 97 ordi-
nary). There was no statistically signiﬁcant difference between
the scores of two groups. The expected costs a patient in the deci-
sion model were estimated as US$4072 (US$ = JPY110) for the
stepped care, and US$2695 for the ordinary care with the dis-
count of 3% a year in three years. The incremental cost-
effectiveness ratio was US$17,636 in terms of cost per patient
prevented from becoming Type-2 diabetes. CONCLUSIONS:
The analysis on the JDPP intermediate report suggested that the
stepped care resulted in increased costs for prevention compar-
ing to the ordinary care in three years, maintaining the same level
of QOLs in both groups.
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COST-EFFECTIVENESS OF MONO- AND COMBINATION
THERAPY WITH PIOGLITAZONE COMPARED TO GLICLAZIDE
IN PATIENTS WITH TYPE-2-DIABETES MELLITUS FROM A
GERMAN STATUTORY HEALTH CARE PERSPECTIVE
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OBJECTIVES: Pioglitazone (PIO), a PPARã-Agonist has been
approved in Germany for treatment of patients with Type-2-
diabetes in mono-and combination therapy with either meformin
(MET) or sulfonylurea. Long-term studies with a treatment
period of 104 weeks involving 1197 patients comparing PIO
with Gliclazide (GLIC) have recently been published. These
studies revealed a superior effect of PIO in sustaining the HbA1C
reduction compared to GLIC. Whether this translates to beneﬁts
with regard to cost-effectiveness is currently unknown.
METHODS: This study compared the clinical effects and costs
of PIO (15–45mg) combination therapy (MET) and 30–45mg
monotherapy with GLIC + MET or GLIC monotherapy, respec-
tively. The validated IMIB Markov diabetes model was adapted.
The mean time transferring a patient to insulin therapy (MIT),
life expectancy (LE and ÄLE), the related NNT to avoid 1
event/1 death and the incremental cost-effectiveness as cost per
life year gained (C/LYG) discounted at 0% and 5% were calcu-
lated. RESULTS: In monotherapy PIO was associated with a
higher MIT 11.70 vs. 11.39 years and a LE of 15.90 vs. 15.45
years (ÄLE: 0.44 years) vs. GLIC. For PIO vs. GLIC the NNT
to avoid 1 event and 1 death were 32 and 54, respectively. When
leaving the C/LYG undiscounted, PIO dominated GLIC and
amounted to 2997€ (5%) vs. GLIC. In combination therapy PIO
+ MET was associated with a higher MIT 9.73 vs. 9.23 years
and a LE of 15.58 vs. 14.94 years (ÄLE: 0.64 years) compared
to GLIC + MET. For PIO + MET vs. GLIC + MET the NNT to
avoid 1 event and 1 death were 28 and 36, respectively. The
C/LYG for PIO + MET was calculated with 1445€ (0%) and
5480€ (5%) vs. GLIC + MET. CONCLUSIONS: The study indi-
cates that PIO in mono, as well as in combination therapy, is
preferable in terms of health outcomes and cost-effectiveness
compared to GLIC in patients with Type-2-diabetes.
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A COST-EFFECTIVENESS ANALYSIS OF SWITCHING TYPE-2
DIABETES PATIENTS FROM IMMEDIATE-RELEASE
METFORMIN (GLUCOPHAGE®) TO A NEW EXTENDED-
RELEASE FORMULATION OF METFORMIN
(GLUCOPHAGE®XR)
Renaudin C1, Roze S2,Valentine WJ2, Palmer AJ2
1Merck Santé, Lyon, France; 2CORE Center for Outcomes Research,
Binningen/Basel, Switzerland
OBJECTIVES: Glucophage®XR is a new extended-release for-
mulation of metformin which permits once-daily medication.
Clinical studies show that Glucophage®XR demonstrate the
same antihyperglycemic efﬁcacy as immediate-release metformin
(Glucophage®). However, in a retrospective chart review,
patients with type 2 diabetes experienced fewer GI side effects
and comparable or better glycemic control, based on HbA1C
measurement, when switched from Glucophage® to Glu-
cophage®XR. Mean HbA1c values were 7.8%-points before the
switch and 7.5%-points afterwards. The CORE Diabetes Model,
a peer-reviewed, validated, model was used to project the long-
term cost-effectiveness of switching patients from Glucophage®
to Glucophage®XR. METHODS: The CORE Diabetes model
employs standard Markov/Monte Carlo simulation techniques
to describe the long-term incidence and progression of diabetes-
related complications. Transition probabilities were derived from
major diabetes studies. Clinical effects of switching from Glu-
cophage® to Glucophage®XR were derived from a retrospec-
tive database study. The analysis was performed using published
UK-speciﬁc costs, health care resource utilization, clinical data
and recommended discount rates of 3.5% for costs and clinical
outcomes. A lifetime horizon and NHS payer perspective was
taken. Only direct costs were considered. Sensitivity analyses
were performed. RESULTS: Switching patients from Glu-
cophage® to Glucophage®XR was projected to improve life
expectancy by 0.10 years, quality-adjusted life expectancy by
0.09 years, and decrease overall lifetime costs by £201/patient.
Results were most sensitive to variations in assumptions about
changes in HbA1c when patients are switched from Glu-
cophage® to Glucophage®XR, and the relative costs of treat-
ment. CONCLUSIONS: In real life, due to improved tolerability,
compliance, and glycemic control, switching patients from Glu-
cophage® to Glucophage®XR may improve longterm patient
outcomes and lead to overall cost savings.
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EFFECT OF PATIENT EDUCATION IN TYPE-2 DIABETES OVER
10 YEARS BASED ON A PROSPECTIVE DIABETES MODEL IN
THE PROVINCE OF STYRIA,AUSTRIA
Habacher W1, Palmer AJ2, Pieber TR1, Rakovac I1, Fritz C1,
Gfrerer R1, Roze S2
1Joanneum Research, Graz, Austria; 2CORE Center for Outcomes
Research, Binningen/Basel, Switzerland
OBJECTIVES: In the province of Styria, Austria, a structured
patient education program for patients with type-2 diabetes was
established in the year 2000. In this open label, prospective
cohort study (n = 1150) follow-up data after one year have been
analysed to document the potential effects over 10 years using
the CORE-Diabetes Model, a validated, peer reviewed simula-
tion model. Patients outcomes and total costs were calculated.
METHODS: A Styria-wide patient education program for type-
2 diabetes was established for general practitioners to improve
treatment outcomes in diabetes care. The program is funded by
the public health care system and a standardised documentation
at baseline and after one year was used. Intermediate results after
one year were incorporated in the CORE diabetes model and
linked with Austria speciﬁc cost data. Monte-Carlo-Simulation
(n = 5.000) over ten years projected long term effects of single
patient education. A virtual control group was assumed to be
treated like general Styrian diabetic population. Discount rate
was 5 % annually. RESULTS: The average life expectancy
increased by 0.29 years (7.32 ± 3.48 vs. 7.03 ± 3.5) under edu-
cation, the total costs over ten years decreased by 774€ per
patient (20,496€ ± 30,335€ vs. 21,270€ ± 37,917€) or 3.8%.
Patient education leads to improved foot care and retinal screen-
